Treatment Guidelines from The Medical Letter
FROM
ISSUE
137
Issue 137
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Drugs for Lipids

New guidelines from the American College of Cardiology and American Heart Association no longer recommend using specific cholesterol targets in the treatment of hyperlipidemia.1 HMG-CoA reductase inhibitors (statins) are the lipid-lowering drugs of first choice for treatment of most patients with atherosclerotic cardiovascular disease. They can decrease the incidence of major coronary events and death in such patients. Taken as an adjunct to diet, exercise, and smoking cessation, statins can also reduce the risk of first cardiovascular events and death in patients with risk factors such as elevated levels of low-density lipoprotein cholesterol (LDL-C) and diabetes. Their benefits in these patients clearly outweigh their adverse effects. Combining a statin with another LDL-C lowering drug, such as colesevelam, niacin, or ezetimibe, can reduce LDL-C levels further than a statin alone, but studies demonstrating ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 137
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian